

K144



THE EXPLORATORY CLINICAL DEVELOPMENT OF
TUCARESOL, AN ANTISICKLING AGENT, USING A NOVEL
SURROGATE MARKER.

A thesis submitted in February 1995, in accordance

with the conditions governing candidates

for the degree of

Doctor of Medicine

in the

University of Adelaide

by

Paul Edward Rolan

M.B.B.S., F.R.A.C.P.

Department of Clinical Pharmacology

Wellcome Research Laboratories,

Beckenham, Kent, UK.

CONTENTS

ABSTRACT	x
DECLARATION	xiv
DEDICATION	xvi
ACKNOWLEDGEMENTS	xvii
GLOSSARY	xix
CHAPTER 1	
INTRODUCTION	1
1.1 Introduction	2
1.1.1 The role of the clinical pharmacologist in exploratory drug development	2
1.2 Sickle Cell Anaemia	8
1.3 A review of potential antisickling therapies	10
1.3.1 Gelation inhibitors	11
1.3.2 Cell-sickling inhibitors	23
1.3.3 Inhibitors of microvascular entrapment	24
1.3.4 Other treatments	26
1.4 Discussion	28

CHAPTER 2

THE PHARMACY, PRECLINICAL PHARMACOLOGY,

PHARMACOKINETICS AND TOXICOLOGY OF TUCARESOL	30
2.1 Introduction	31
2.2 Physical properties of tucaresol	31
2.3 Biochemistry: interaction with haemoglobin	32
2.4 Pharmacology	33
2.4.1 <i>In vitro</i> / <i>ex vivo</i>	33
2.4.2 Whole animal	38
2.5. Toxicology	42
2.5.1 Acute i.v	42
2.5.2 Acute oral	43
2.5.3 Subacute oral	43
2.5.4 One month	44
2.5.5 Teratogenicity	54
2.5.6 Mutagenicity.	57
2.6 Pharmacokinetics	58
2.6.1 Rat	58
2.6.2 Rabbit.	60
2.6.3 Dog	60
2.6.4 Monkey	61
2.7 Conclusions	62

CHAPTER 3

THE CLINICAL PHARMACOLOGY OF VALERESOL	64
3.1 Introduction	65
3.2 Summary of preclinical data of valeresol	65
3.2.1 Pharmacology	65
3.2.2 Toxicology	65
3.2.3 Pharmacokinetics	66
3.3 Human studies with valeresol	66
3.3.1 First human study	66
3.3.2 Study in sickle cell disease patients	67
3.3.3 Effects on moderate graded exercise in healthy volunteers	68
3.3.4 Effects on anaerobic threshold in healthy volunteers	71
3.4 Conclusions	74

CHAPTER 4

THE PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF SINGLE ORAL DOSES OF TUCARESOL IN HEALTHY MALE VOLUNTEERS	75
4.1 Introduction and Objectives	76
4.2 Study Design	76
4.2.1 General	77
4.2.2 Design Considerations	77
4.3 Subjects, Protocol and Methods	80

4.3.1 Subjects	80
4.3.2 Protocol	81
4.3.3 Study Drug	82
4.3.4 Laboratory methods	82
4.3.5 Clinical Measurements	84
4.3.6 Data Analysis	85
4.4 Results	86
4.4.1 Volunteer accountability and demographics	86
4.4.2 Pharmacokinetics	86
4.4.3 Haemoglobin Modification - %MOD	88
4.4.4 Tolerability and Adverse Experiences	88
4.4.5 Haematology	88
4.4.6 Cardiovascular Parameters	89
4.4.7 Other Tests	89
4.5 Discussion	89
4.6 Conclusions	93
TABLES	94
FIGURES	97

CHAPTER 5

THE EFFECTS OF A TITRATED LOADING DOSE OF TUCARESOL IN

HEALTHY MALE VOLUNTEERS	105
5.1 Introduction and Rationale	106
5.2 Objectives	106

5.3 Study design	106
5.3.1 General	106
5.3.2 Design considerations	108
5.3.3 Statistical considerations	108
5.3.4 Exercise tests	109
5.3.5 Psychometric tests	110
5.3.6 Safety considerations	110
5.4 Subjects, Protocol and Methods	110
5.4.1 Subjects	110
5.4.2 Protocol	111
5.4.3 Study drug	111
5.4.4 Drug administration and dosages	111
5.4.5 Schedule	114
5.4.6 Laboratory Methods	115
5.4.7 Clinical measurements and procedures	115
5.4.8 Data analysis	119
5.5 Results	121
5.5.1 Subjects	121
5.5.2 Protocol compliance and modifications	121
5.5.3 Doses administered	121
5.5.4 Pharmacokinetics	122
5.5.5 Haemoglobin modification - %MOD	122
5.5.6 Cardiovascular and psychometric data	123
5.5.7 Adverse experiences	128

5.5.8 Haematology, Plasma Biochemistry and Viral Serology . . .	130
5.6 Discussion	132
5.7 Conclusions	137
TABLES	139
FIGURES	155

CHAPTER 6

THE PHARMACOKINETICS, TOLERABILITY AND EFFECTS ON

HAEMOLYSIS OF MULTIPLE DOSES OF TUCARESOL IN PATIENTS WITH

SICKLE CELL DISEASE 169

6.1 Introduction	170
6.2 Objectives	171
6.3 Study Design	172
6.3.1 General	172
6.3.2 Design considerations	173
6.4 Subjects, Protocol and Methods	175
6.4.1 Subjects	175
6.4.2 Protocol	176
6.4.3 Drug Administration and Dosages	176
6.4.4 Schedule	179
6.4.5 Clinical measurements and procedures	180
6.4.6 Laboratory methods	181
6.4.7 Data analysis	182
6.5 Results	182

6.5.1 Subjects	182
6.5.2 Protocol compliance and modifications	183
6.5.3 Doses administered	184
6.5.4 Pharmacokinetics	184
6.5.5 Haemoglobin modification - %MOD	185
6.5.6 Haematology	185
6.5.7 Adverse experiences	188
6.5.8 Biochemistry	191
6.5.9 Exercise tests	192
6.6 Discussion	192
6.7 Conclusions	197
TABLES	199
FIGURES	212

CHAPTER 7

DISCUSSION	222
7.1 The exploratory clinical development of tucaresol using a surrogate marker	223
7.2 Future clinical development of tucaresol as a treatment for sickle cell disease	224
7.3 Tucaresol as an immunopotentiator	226
7.3.1 Immunological effects of tucaresol <i>in vitro</i>	228
7.3.2 Immunological effects of tucaresol <i>in vivo</i>	228
7.3.3 Antiviral effects of tucaresol	228

7.3.4 Antitumour effects of tucaresol	229
7.3.5 Potential clinical uses for tucaresol as an immunopotentiator	229
7.4 Conclusions	230
 BIBLIOGRAPHY	 232

APPENDICES - Papers arising from original work presented in this thesis.

Appendix A.

Rolan PE, Parker JE, Gray SJ, Weatherley BC, Ingram J, Leavens W, Wootton R and Posner J (1993).

The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl]benzoic acid), a potential antisickling agent, following oral administration to healthy volunteers. British Journal of Clinical Pharmacology 35:419-425.

Appendix B.

Rolan PE, Mercer AJ, Wootton R and Posner J (1995).

Pharmacokinetics and pharmacodynamics of multiple oral doses of tucaresol, an antisickling agent, in healthy volunteers. British Journal of Clinical Pharmacology 39:375-380.

ABSTRACT

1. Sickle cell disease is a family of inherited haemoglobinopathies resulting from a point mutation in the gene coding for the β -chain of haemoglobin, resulting in the substitution of valine for glutamate as the sixth amino acid residue on the β -chain. Sickle haemoglobin (HbS) containing the abnormal β -chain, functions much like normal haemoglobin (HbA) when oxygenated, but when de-oxygenated, HbS polymerises into helical fibres which distort the normal discoid shape of the red blood cell into a "sickle" shape. It is widely believed that a treatment which prevents polymerisation of deoxy HbS *in vivo* would improve the clinical manifestations of the disease.

2. Tucaresol (4(2-formyl-3-hydroxy-phenoxy)methyl)benzoic acid) was designed to bind preferentially to the oxy-conformation of human haemoglobin at a site between the amino terminal residues of the α -subunits, stabilising haemoglobin in the oxy-conformation. This results in a left-shift of the haemoglobin oxygen saturation curve (OSC), increasing the proportion of oxy-Hb at any given low oxygen tension, thereby offering the possibility of preventing sickling *in vivo*.

3. A new surrogate marker (%MOD) had previously been developed to assess the effect of tucaresol and related compounds in man. %MOD is defined as the proportion of haemoglobin molecules reacted with haemoglobin to a high affinity form. It is measured by comparing observed OSC's *ex vivo* with a series of template curves ranging from 0%MOD to 100%MOD in 5% increments. From analysis of the kinetics of formation of the sickle polymer it was estimated that 15 - 30 % MOD would be required for the effective prophylaxis of the manifestations of the disease.

4. This thesis describes the exploratory clinical development of tucaresol, consisting of the three studies performed in man to the date of writing. The first human study with tucaresol was of open, single-dose, ascending-dose, crossover design in 9 healthy male volunteers. Doses ranged from 200 - 3600 mg. Peak concentrations in plasma and erythrocytes were linearly related to dose but were approximately an order of magnitude higher in erythrocytes than in plasma. There was evidence of distribution of drug from plasma to erythrocytes over 24 hours from dosing. Terminal elimination half-life was approximately twice as long from plasma than from erythrocytes, with mean values after the top dose of 289 and 151 h respectively. At the highest dose, peak %MOD was between 19-26%. The drug was well tolerated, with only minor gastrointestinal discomfort at high doses. There were no clear effects on routine haematology and biochemistry, platelet aggregation, resting or exercise heart rates or blood pressures.

5. The second human study was of placebo-controlled, parallel-groups design in 12 healthy male volunteers. The 8 subjects on active drug received three doses of tucaresol at 48 hour intervals. The first was estimated by body weight to achieve 15 % MOD, and the subsequent two doses were individually titrated to produce 25 and 32.5 % MOD. Mean peak achieved %MOD was 34%. Pharmacokinetics were similar to those in the previous study. There was a small increase in heart rate after exercise in the tucaresol group compared to the placebo group. A major unexpected finding was the development of a syndrome of rash, fever and tender cervical lymphadenopathy with onset 7-10 days from dosing suggesting an immune mechanism.

6. The third human study was of double-blind, placebo-controlled, parallel-groups design in 12 stable patients with sickle cell disease. Cumulative doses were progressively reduced from 6400 and 4000 mg over 10 days in the first pair of subjects, to 3000 in the next four patients and 500 mg in the last pair because of rapid rise in haemoglobin and adverse experiences at the higher doses. The pharmacokinetics of tucaresol were similar to those in healthy volunteers, but there was a trend for reduced clearance in women compared to men. Peak % MOD values were 23 and 24%. Three subjects developed fever and tender cervical lymphadenopathy within 7-10 days from the start of dosing. Two were treated with prednisolone with prompt resolution of symptoms. In all six subjects attaining >10% MOD there was evidence of an antisickling effect of tucaresol, evidenced by rises in haemoglobin, falls in irreversibly sickled cell counts, plasma lactate dehydrogenase and bilirubin.

7. Subsequent *in vitro* and animal studies investigated the possible effects of tucaresol on the immune system. Tucaresol was found to have powerful immunostimulant properties with antiviral and antitumour effects. The likely mechanism was the formation of Schiff's-base adducts with helper T cells mimicking the Schiff's-base mediated communication between antigen-presenting cells and helper T cells. Further evaluation of tucaresol in chronic viral infections and possibly cancer is warranted.

8. This thesis demonstrates that rational drug design may be an efficient way of selecting potential therapeutic candidates. A mechanistically-based surrogate may be very helpful in comparing pharmacology and kinetic studies between animals and man

and help design dosage regimens. However, the clinical pharmacologist in exploratory development needs to look for effects other than those expected.